View latest PathMap Research

DISCLAIMER: This data is not peer reviewed and is NOT professional advice.
Original Text Evaluated

What dietary habits are beneficial towards reducing excess/harmful tyramine in order to improve liver and gut health?

Plausibility Verdicts

Evaluation 1

Reduce intake of fermented/marinated foods prone to psychrotrophic bacterial growth, implement low-protein dietary patterns, and utilize specific probiotic strains like L. plantarum and L. acidophilus to modulate gut microbiota.

Evaluation 2

To reduce harmful tyramine, shift toward diets rich in fiber, vegetables, and PUFAs, while limiting simple sugars and processed foods. Utilizing fermented products prepared with specialized starter cultures and probiotic supplementation can further optimize microbial health and decrease tyramine production.

Evaluation 3

Reducing dietary and gut-microbial derived tyramine involves consuming fermented foods produced by amine-negative starter strains, increasing fiber intake to favor carbohydrate fermentation over amino acid fermentation, and utilizing specific prebiotic interventions to rebalance the gut microbiota.

Dataset Summary

Novel & Overlooked Insights

  • Tyramine is not inherently "bad"; it acts as a ligand for TAAR1, and in specific postprandial contexts, it can even exert anorexigenic (appetite-suppressing) effects via the hypothalamus.
  • The "harmfulness" of tyramine is context-dependent, relying heavily on the integrity of the intestinal barrier and the presence of specific receptors like ADRA2A in stem cells.
  • Marination of foods (like fish) significantly increases tyramine concentrations, suggesting that kitchen preparation methods are as important as the raw ingredients themselves.
  • Enterococcaceae are identified as major drivers of tyramine production post-bariatric surgery, a key risk factor for colorectal cancer.
  • Sulfonation is a natural detoxification pathway, and gut microbes possess enzymes (ASSTs) that can regulate the concentrations of tyramine sulfate.
  • Low-protein diets (VLP) can specifically reduce the cecal bioamine load in porcine models, suggesting a broader potential for human metabolic health.
  • Probiotic supplementation with *Lactobacillus acidophilus* and *Lactiplantibacillus plantarum* is highly efficient, capable of reducing total biogenic amine levels by up to 80%.
  • Tyramine oxidation is a specific metabolic function attributed to *Pseudomonas* species within the microbiome.
  • Fermented foods, often criticized for high amine content, can be optimized using specific starter cultures like *Bacillus velezensis* A1 to drastically reduce biogenic amine levels.
  • The TAAR1 receptor pathway serves as a sensing mechanism for trace amines like tyramine, where inhibition (e.g., via EPPTB) can mitigate colitis symptoms.
  • High dietary intake of simple sugars is linked to a shift in microbiome dynamics, reducing the necessity for microbial cooperation and favoring potentially hostile, amine-producing ecological interactions.
  • The use of iron oxide chitosan nanoparticles (GTPP-IOCHNP) enhances the bioavailability of green tea polyphenols, which modulate hepatic protein expression and inhibit cytochrome P450 enzymes involved in metabolic drug handling.
  • Dietary patterns following UK-DRV index guidelines, emphasizing fish and fiber, correlate with reduced NAFLD prevalence.
  • Specific probiotic combinations, such as *Lactobacillus acidophilus* and *Lactiplantibacillus plantarum*, can achieve up to an 80% reduction in total biogenic amine levels during food fermentation.
  • The gut microbiota can be reconfigured by prebiotic interventions (e.g., squid-derived chondroitin sulfate) to shift the metabolome toward beneficial short-chain fatty acids (SCFAs) and away from harmful metabolites like tyramine.
  • Fermented soybean paste (Doenjang) has been shown to reduce biogenic amine-induced liver damage and improve survival rates in obese mouse models of NAFLD.
  • The presence of tyramine in the gut is not exclusively endogenous; certain dietary inputs can directly increase amine levels if the microbiota environment favors amino acid fermentation over carbohydrate fermentation.
  • Inhibitors of trace amine signaling, such as the TAAR1 antagonist EPPTB, show potential in alleviating colitis symptoms by suppressing the downstream effects of elevated gut trace amines.
  • Metabolic profiling of gut ecosystems in diseased populations reveals that tyramine production is often linked to the down-regulation of beneficial metabolic pathways, such as riboflavin metabolism in pediatric non-organic anorexia.
  • Microbiome-host interactions indicate that even in the absence of exogenous dietary tyramine, high-fat diets can promote the proliferation of tyramine-producing bacteria, worsening liver fibrosis and inflammation.

Extracted Discoveries

Suggested Experiments
  • Assess the efficacy of VLP (very low protein) diets in human subjects with existing MASLD on fecal tyramine levels and liver enzyme profiles.
  • Conduct a longitudinal study comparing fermented dairy products with and without tyramine-suppressing adjunct starter cultures on the gut metabolome.
  • Examine the impact of specific prebiotic beta-glucans on tyramine-producing *Enterococcus* populations using metagenomic sequencing.
  • Quantify luminal tyramine levels in individuals adhering to low-sugar, high-fiber diets vs. industrialized diet controls.
  • Assess the efficacy of Pseudomonas-based supplementation in neutralizing excess tyramine in murine models of high-fat diet-induced dysbiosis.
  • Evaluate the impact of Bacillus velezensis A1 inoculation on the gut microbiome profile and systemic inflammatory markers in human subjects.
  • Assess the longitudinal effect of specific fiber-rich diets on tyramine decarboxylase activity in the human colon using metagenomic functional profiling.
  • Compare the efficacy of different probiotic consortia in reducing intestinal tyramine concentrations in MASLD patients.
Suggested Studies
  • A systematic randomized controlled trial (RCT) evaluating the effect of dietary tyramine restriction on intestinal barrier permeability in patients post-RYGB surgery.
  • A cohort study investigating the correlation between long-term consumption of high-tyramine fermented foods and the development of non-alcoholic liver pathology.
  • Evaluation of the TAAR1-serotonin axis in human patients with pediatric inflammatory bowel disease following probiotic intervention.
  • A prospective longitudinal study correlating long-term dietary inflammatory index (DII) scores with fecal tyramine concentrations and colorectal cancer risk.
  • A clinical intervention trial investigating the effects of specific fiber types (e.g., oat hulls vs. sugar beet pulp) on luminal tyramine-producing microbiota in patients with IBD.
  • A randomized controlled clinical trial measuring fecal tyramine concentration in patients with NAFLD following supplementation with identified amine-negative probiotic strains.
  • Cross-sectional metabolic mapping study to correlate dietary fiber intake types with luminal tyramine levels in diverse populations.
Swansons Literature Based Discovery Candidates
  • Probiotic-mediated normalization of TAAR1 signaling in the gut may reduce the severity of diet-induced obesity (DIO) and secondary insulin resistance.
  • Role of TAAR1 in IBD and immune homeostasis (ID: 30013475, 41550498)
  • Anti-obesity effects of tyramine in HFD models (ID: 38965418)
  • TAAR1 signaling pathway in the enteric nervous system (ENS).
  • Since HFD induces obesity via metabolic pathways and tyramine acts on TAAR1 to improve insulin sensitivity, the use of probiotics to modulate this endogenous signaling system provides a hidden link between diet-induced microbial dysbiosis and metabolic disease mitigation.
  • Dietary intake of specific sulfur-donating prebiotics can enhance the sulfonation activity of the gut microbiome, thereby sequestering luminal tyramine into tyramine-sulfate.
  • Gut microbial sulfotransferases (ASSTs) from Bacteroides vulgatus modulate concentrations of donor phenolic sulfates (ID: 41552834).
  • Genotoxic luminal tyramine levels contribute to CRC and IBD pathogenesis (ID: 42283770).
  • Sulfotransferase-mediated conjugation of phenolic amines.
  • The gut microbial ASST enzymes demonstrate broad substrate flexibility, including tyramine. Increasing sulfur-containing substrate availability (sulfur donor substrates) may promote the microbial sequestration of free tyramine into less reactive, non-genotoxic tyramine-sulfate derivatives.
  • Discovered Hypothesis (A to C): Dietary supplementation with specific amine-negative probiotic strains can mitigate the genotoxic effect of high-protein diets in the distal colon, thereby reducing colorectal cancer (CRC) risk. - Literature A (Origin): Identification of amine-negative probiotic strains such as Pediococcus pentosaceus L1 that do not synthesize biogenic amines (Source: 41191059). - Literature C (Target): Anatomical bypass and proteolytic fermentation (as seen in RYGB surgery) increase CRC risk through the genotoxic luminal environment characterized by tyramine (Source: 42283770). - The Intersecting Bridge B: Gut microbial amino acid fermentation and its resulting metabolic byproducts (tyramine). - Biological Rationale: By introducing strains that lack decarboxylase activity, one can functionally decouple protein-rich dietary intake from the generation of genotoxic amines in the distal colon, potentially reversing the inflammatory/pro-carcinogenic metabolite shift caused by distal substrate overload.
Contradictions Between Evidences
  • There is a tension regarding the role of tyramine: while generally considered pathogenic in MASLD/colitis (IDs: 38738766, 38788722), it is identified as a beneficial anorexigenic metabolite in obesity/diabetes models (ID: 38965418, 41857429). The benefit seems to depend on host receptor availability and intestinal integrity.
  • Evidence regarding specific protein intake is inconsistent; while plant protein is associated with reduced GDM risk, high total protein consumption in other contexts may have neutral or varying metabolic effects. No specific direct contradiction on tyramine, but potential trade-offs between fermentation health and amine production exist.
  • There is no direct contradiction; however, some sources suggest that certain types of fermentation (e.g., citrus pectin vs. FOS) may differentially promote amino acid fermentation and increase tyramine, indicating that 'fermented' is not a monolith and requires specific strain and substrate selection.
Repurposed Solutions
  • Repurposing Selegiline or other MAO-B inhibitors to treat MASLD by modulating oxidative stress, as MAO-B is involved in the deamination of amines like tyramine (ID: 42022562).
  • Repurpose fermented food starter strains, specifically Bacillus velezensis A1 (originally for douchi), to mitigate tyramine levels in broader processed meat applications, thereby reducing the genotoxic risk identified in other high-protein processed foods.
  • Probiotic strains originally identified for their safety in dairy and meat processing (e.g., L. helveticus, L. rhamnosus) can be repurposed as therapeutic agents to target gut-brain axis dysregulation and hepatic inflammation in metabolic disease.
Support open science: Order your own dataset here.

Perfect for thesis ideas and a base concept for academic writings!

Each package comes with guaranteed unpublished discoveries!

Order now - $29.99

PathMap is funded by sales of datasets and coversheets to researchers of any kind who wish to discover the most viable routes and paths to accelerate cures. We do not make theoretical molecules, we expose the truth in current PubMed literature. Commission a trace today.

Investigator Profile

👨‍🔬
Joshua Dungan
PathMap Admin
PathMap PathMap Image